Wed, May 21, 10:13 AM (26 days ago)
### Summary of Haemonetics Corporation (HAE) Financial Performance **Financial Performance:** - **Revenue:** $1,360.8 million for fiscal 2025, up 4.0% from fiscal 2024. - **Gross Profit:** $748.9 million, representing 55.0% of net revenues. - **Operating Income:** $221.8 million, a 34.5% increase from fiscal 2024. - **Net Income:** $167.7 million, a 42.6% increase from fiscal 2024. - **Earnings per Share (EPS):** Basic EPS was $3.33, and diluted EPS was $3.31. **Segment Performance:** - **Plasma:** Revenue decreased by 6.0% due to lower sales volumes in North America. - **Blood Center:** Revenue decreased by 7.8% due to declines in the Whole Blood business. - **Hospital:** Revenue increased by 23.7% due to growth in Interventional Technologies and Blood Management Technologies. **Operating Expenses:** - **Research and Development:** $62.7 million, up 15.2%. - **Selling, General, and Administrative:** $436.8 million, up 1.2%. - **Amortization of Acquired Intangible Assets:** $48.3 million, up 50.7%. - **Remeasurement of Contingent Consideration:** $(23.0) million, a benefit. - **Impairment of Intangible Assets:** $2.4 million. **Cash Flow:** - **Operating Activities:** $181.7 million. - **Investing Activities:** $(161.9) million. - **Financing Activities:** $108.8 million. **Debt and Liquidity:** - **Cash and Cash Equivalents:** $306.8 million. - **Debt:** $921.2 million in long-term debt, $303.6 million in short-term debt. - **Share Repurchase:** $500 million authorization over three years. **Risk Factors:** - **Market Risks:** Competition, regulatory changes, and economic conditions. - **Operational Risks:** Supply chain disruptions, raw material availability, and manufacturing challenges. - **Financial Risks:** Debt obligations, interest rate fluctuations, and currency exchange risks. **Strategic Overview:** - **Acquisitions:** Attune Medical and OpSens Inc. to expand product portfolios. - **Divestitures:** Sale of the Whole Blood product line to GVS, S.p.A. - **Market and Regional Alignment Initiative:** Aimed at improving operational performance and reducing costs. **Future Outlook:** - **Growth Potential:** Plasma and Hospital segments are expected to drive long-term value. - **Innovation:** Continued investment in research and development. - **Market Position:** Strengthening presence in key markets and expanding product offerings. **Market Position Changes:** - **Competitive Landscape:** Intensifying competition in automated blood component collection and plasma collection markets. - **Regulatory Environment:** Adapting to stringent regulations and compliance requirements. **Financial Condition:** - **Liquidity:** Sufficient cash and cash equivalents to meet short-term obligations. - **Debt Management:** Compliance with debt covenants and strategic use of financing. **Note:** All amounts are in thousands, except per share data.